脂肪细胞来源CTRP3通过LAMP1-STAT3轴在银屑病中发挥抗炎作用
研究发现银屑病患者循环CTRP3水平显著低于健康对照,且与代谢危险因素负相关。在咪喹莫特诱导的小鼠模型中,恢复CTRP3水平可减轻银屑病症状;CTRP3通过LAMP1阻断STAT3磷酸化,直接抑制银屑病角质形成细胞的炎症反应。IL-17A和TNF-α可损害脂肪细胞分化及CTRP3分泌,揭示银屑病与代谢紊乱之间的恶性循环机制。
要点
- 银屑病患者循环CTRP3水平降低,且与代谢危险因素负相关
- CTRP3通过LAMP1阻断STAT3磷酸化,抑制角质形成细胞炎症
- IL-17A和TNF-α损害脂肪细胞分化及CTRP3分泌,形成恶性循环
核心结论
- 脂肪细胞功能障碍及IL-17A导致的CTRP3低水平加剧银屑病进展及相关代谢综合征,揭示银屑病与代谢紊乱之间的恶性循环机制。
研究设计与样本
- 研究比较银屑病患者与健康对照的循环CTRP3水平,并在饮食诱导肥胖小鼠和正常饮食小鼠的咪喹莫特诱导银屑病模型中,通过GLP-1受体激动剂exendin-4恢复CTRP3水平或局部应用CTRP3,结合体外实验探究机制。
主要发现
- 银屑病患者循环CTRP3水平显著低于健康对照,且与代谢危险因素负相关。
- 在饮食诱导肥胖小鼠中,用GLP-1受体激动剂exendin-4恢复CTRP3水平可减轻咪喹莫特诱导的银屑病症状。
- 局部应用CTRP3对正常饮食小鼠的咪喹莫特诱导银屑病有保护作用。
- CTRP3通过LAMP1阻断STAT3磷酸化,直接抑制银屑病角质形成细胞的炎症反应。
- IL-17A和TNF-α损害脂肪细胞分化及足够CTRP3的分泌。
临床怎么用
- 改善肥胖银屑病患者CTRP3水平的药物可能作为银屑病治疗的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is a systemic disease that is associated with metabolic disorders, which may contribute to abnormal adipokine levels. However, the underlying mechanism is largely unknown. Here, we investigated the role of the adipokine CTRP3 in the pathogenesis of psoriasis and comorbidities. The circulating CTRP3 level in patients with psoriasis was significantly lower than that in healthy controls and negatively correlated with metabolic risk factors. Rescuing CTRP3 levels with the GLP-1 receptor agonist exendin-4 in diet-induced obese mice could alleviate its more severe psoriatic symptoms in an imiquimod-induced mouse model. Topical application of CTRP3 also exerted a protective effect on imiquimod-induced normal diet mice. Moreover, CTRP3 could directly inhibit the inflammatory responses of psoriatic keratinocytes by blocking phosphorylation of signal transducer and activator of transcription 3 via LAMP1 in vitro. We identified the critical psoriatic cytokines, including IL-17A and TNF-α, that impaired adipocyte differentiation and sufficient CTRP3 secretion. In sum, our study reveals that adipocyte dysfunction and low level of CTRP3 caused by IL-17A exacerbates psoriasis progression and related metabolic syndrome, implying a mechanism underlying the vicious cycle between psoriasis and metabolic disorders. Pharmacological agents that improve CTRP3 level in obese patients with psoriasis may be considered as a potential strategy for psoriasis treatment.
引用
- Xue K, Shao S, Fang H, et al. Adipocyte-Derived CTRP3 Exhibits Anti-Inflammatory Effects via LAMP1-STAT3 Axis in Psoriasis. J Invest Dermatol. 2021. PMID: 34687744. doi:10.1016/j.jid.2021.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。